Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1711
    +0.0017 (+0.15%)
     
  • GBP/USD

    1.2620
    -0.0002 (-0.02%)
     
  • Bitcoin GBP

    55,560.98
    +307.13 (+0.56%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,505.56
    +337.49 (+0.84%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

Merck KGaA sells allergy unit to Dermapharm, keeps autoinjector project

FRANKFURT (Reuters) - German drugmaker Merck KGaA <MRCG.DE> agreed to sell its allergy business Allergopharma to Dermapharm SE <DMPG.DE> for an undisclosed price but will continue to develop an autoinjector to treat allergic shock.

The deal over Allergopharma, which generated sales of 88 million euros in 2018, will likely be closed by the end of the second quarter, Merck said in a statement on Wednesday.

Merck's Allergopharma had been working for years on an adrenaline autoinjector for the treatment of anaphylactic reactions that could compete with Mylan's <MYL.O> EpiPen allergy shot for self administration.

Dermapharm is a family-controlled maker of generic drugs, cosmetics, dietary products and medical devices that went public two years ago.

(Reporting by Ludwig Burger; Editing by Christoph Steitz)